IGMS IGM Biosciences Inc

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March 26, 2020.

In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 26, 2020, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 2991398Domestic Dial-in Number: (866) 649-1996International Dial-in Number: (409) 217-8769Live Webcast: https://edge.media-server.com/mmc/p/vw87ve5n

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.igmbio.com.

About IGM Biosciences, Inc. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners David Pitts212-600-1902 igmbio@argotpartners.com